What do systematic reviews say?

Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease

Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease

Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

Incidence of serious adverse events ‐ not reported · adults with alopecia areata

Incidence of serious adverse events ‐ not reported · adults with alopecia areata

Total number of serious adverse events not measured · patients with osteoarthritis

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis

Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis

Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis

Adverse events: serious adverse events ‐ not reported · patients with schizophrenia

Serious adverse events ‐ Haemodilution versus control. · patients with liver resection.

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds

Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds

Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds

Serious adverse events during the study period · children with acute postoperative pain

Serious adverse events during the study period · children with acute postoperative pain